RxDoctor Payments Data

David Ewing, MD

Neurology · Saint Joseph, MONPI 1639283369

Payments from drug & device makers

$23,491in general payments, 2019–2025

Across 760 payments — averaging $30.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Harmony Biosciences LLC$1K
  • Biogen$899
  • UCB, Inc.$882
  • EMD Serono, Inc.$552
  • AstraZeneca$411
  • plus $6K from 53 others

What the payments were for

  • Consulting fees$1,2305%
  • Speaking & faculty fees$9,52541%
  • Travel & lodging$7613%
  • Food & beverage$11,77350%
  • Education$2021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)230$12,930
Harmony Biosciences LLC5$1,321
Biogen56$899
UCB, Inc.50$882
EMD Serono, Inc.32$552
AstraZeneca19$411
Novartis20$386
Medtronic(2 entities)10$373
Amgen18$328
Eisai Inc.13$308
Lilly USA, LLC16$305
Teva Pharmaceuticals USA, Inc.15$272
Sanofi16$267
Argenx US, Inc.12$262
Biohaven Pharmaceuticals, Inc.20$239
Pfizer33$225
Biohaven Pharmaceutical Holding Company Ltd.19$215
Acadia Pharmaceuticals Inc12$205
Bristol Myers Squibb11$200
Genentech USA, Inc.12$188
Grifols USA, LLC9$187
Abbott9$187
Jazz Pharmaceuticals Inc.9$179
Johnson & Johnson(2 entities)7$169
Sumitomo Pharma America, Inc.10$163
Kyowa Kirin, Inc.8$146
ANI Pharmaceuticals, Inc.6$142
Neurocrine Biosciences, Inc.6$117
Livanova USA, Inc.6$99
GE HealthCare6$99
Piramal Critical Care1$90
Catalyst Pharmaceuticals, Inc.4$84
Mallinckrodt Hospital Products Inc.5$82
Neurelis, Inc.4$76
Lundbeck LLC4$75
Amneal Pharmaceuticals LLC5$72
Otsuka America Pharmaceutical, Inc.4$72
Corium, LLC3$64
TG Therapeutics, Inc.2$62
Acorda Therapeutics, Inc3$54
Scilex Pharmaceuticals Inc.3$53
MDD US Operations, LLC2$53
Sunovion Pharmaceuticals Inc.4$47
Axsome Therapeutics, Inc.2$38
Microtransponder, Inc.1$33
E.r. Squibb & Sons, L.L.C.2$30
Upsher-smith Laboratories LLC2$29
Impel Pharmaceuticals Inc.2$29
Adamas Pharmaceuticals, Inc.2$25
Supernus Pharmaceuticals, Inc.1$25
Greenwich Biosciences, Inc.1$19
Cycle Pharmaceuticals Inc1$18
Boston Scientific1$18
Banner Life Sciences, LLC1$17
Alnylam Pharmaceuticals Inc.1$15
Vertical Pharmaceuticals, LLC1$15
Mallinckrodt Enterprises LLC1$14
Portola Pharmaceuticals, LLC1$12
Avanir Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,491 in reported general payments places this provider in the 75th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$217,060
Medicare patients
878
Services billed
8,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine41$411,475
BriviactBrivaracetam81$109,134
Aimovig AutoinjectorErenumab-Aooe108$91,978
QuliptaAtogepant69$78,051
CopaxoneGlatiramer Acetate12$70,004
Nurtec OdtRimegepant Sulfate47$61,559
Gamunex-CImmune Globul G/Gly/Iga Avg 4626$59,900
Lacosamide450$52,422
GlatopaGlatiramer Acetate14$42,182
FycompaPerampanel36$42,062
UbrelvyUbrogepant32$36,794
VimpatLacosamide16$33,525
Glatiramer Acetate17$31,924
KeppraLevetiracetam20$20,144
AptiomEslicarbazepine Acetate15$19,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$272$481,48053 claims
UCB, Inc.Briviact, Vimpat$882$142,65997 claims
AbbVieQulipta, Ubrelvy$12,930$114,845101 claims
PfizerNurtec Odt$225$61,55947 claims
Grifols USA, LLCGamunex-C$187$59,90026 claims
Eisai Inc.Fycompa$308$42,06236 claims
Sunovion Pharmaceuticals Inc.Aptiom$47$19,87415 claims
Upsher-smith Laboratories LLCTopiramate$29$6,050559 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 381 neurology providers in Missouri.

Other neurology in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →